Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus

Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus

AimsAs metabolic remodeling is a pathological characteristic in type 2 diabetes (T2D), we investigate the roles of newly developed long-acting glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as dulaglutide and liraglutide on metabolic remodeling in patients with recent-onset T2D.MethodsWe...

Full description

Bibliographic Details
Main Authors:	Juan Du, Liuqing Xi, Zhongxiao Zhang, Xiaoxu Ge, Wenyi Li, Wenfang Peng, Xiaohong Jiang, Wen Liu, Nan Zhao, Xingyun Wang, Xirong Guo, Shan Huang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-01-01
Series:	Frontiers in Endocrinology
Subjects:	type 2 diabetes mellitus metabolic remodeling dulaglutide and liraglutide Glycerophospholipids LC-MS
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2022.1097612/full

Similar Items

Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis
by: Kai-Cheng Chang, et al.
Published: (2020-10-01)

Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study
by: S. Ghosal, et al.
Published: (2018-05-01)

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
by: Takahiro Iijima, et al.
Published: (2023-06-01)

Long‐Term Activation of Glucagon‐like peptide‐1 receptor by Dulaglutide Prevents Diabetic Heart Failure and Metabolic Remodeling in Type 2 Diabetes
by: Saiyang Xie, et al.
Published: (2022-10-01)

Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes
by: Yu Su, et al.
Published: (2023-01-01)

Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
by: Courtney H, et al.
Published: (2017-03-01)

Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial
by: Antonino Tuttolomondo, et al.
Published: (2021-01-01)

The use of the GLP-1 analog - dulaglutide in the treatment of morbid obesity - case report
by: Agata Juda, et al.
Published: (2022-11-01)

Exacerbation of atrial fibrillation related to dulaglutide use
by: Jayden Lee, et al.
Published: (2021-05-01)

Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
by: Maria Mirabelli, et al.
Published: (2021-03-01)

GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
by: Joshua J. Neumiller, et al.
Published: (2022-07-01)

The impact of preadmission/prediagnosis use of GLP‐1 receptor agonists on COVID‐19 mortality in patients with diabetes: A systematic review and meta‐analysis
by: Chia Siang Kow, et al.
Published: (2023-09-01)

Liraglutide overdose: A case report and an updated review
by: Sharafaldeen Bin Nafisah, et al.
Published: (2020-01-01)

Advances in the treatment of type 2 diabetes: impact of dulaglutide
by: Thompson AM, et al.
Published: (2016-05-01)

Efficacy and safety of dulaglutide: a novel once-weekly glucagon-like peptide-1 analogue
by: A. S. Pogorelova, et al.
Published: (2018-03-01)

Mode of administration of dulaglutide: implications for treatment adherence
by: Amblee A
Published: (2016-06-01)

Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study
by: Torre E, et al.
Published: (2020-04-01)

Dynamic modulations of sphingolipids and glycerophospholipids in COVID‐19
by: Makoto Kurano, et al.
Published: (2022-10-01)

The Acinetobacter baumannii Mla system and glycerophospholipid transport to the outer membrane
by: Cassandra Kamischke, et al.
Published: (2019-01-01)

Efficacy and safety of dulaglutide in patients with absolute insulin deficiency
by: Kutoh Eiji, et al.
Published: (2019-07-01)

Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment
by: Chen S, et al.
Published: (2024-03-01)

Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies
by: Shuichi Suzuki, et al.
Published: (2017-06-01)

Dulaglutide as an Effective Replacement for Prandial Insulin in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Retrospective Review
by: Hwi Seung Kim, et al.
Published: (2021-11-01)

Dulaglutide improves glucocorticoid-induced hyperglycemia in inpatient care and reduces dose and injection frequency of insulin
by: Hiroyuki Uchinuma, et al.
Published: (2020-05-01)

Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment [Letter]
by: Panjaitan NSD, et al.
Published: (2024-04-01)

Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Worsen after the Administration of Dulaglutide
by: Toshitaka Sawamura, et al.
Published: (2022-02-01)

Effect of dulaglutide injection on weight beyond glycemic control: Real-world observational study
by: Adel G. Mohammed, et al.
Published: (2023-02-01)

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
by: Manige Konig, et al.
Published: (2021-09-01)

Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study
by: Ji Young Seo, et al.
Published: (2023-02-01)

Lipidomic and transcriptomic profiles of glycerophospholipid metabolism during Hemerocallis citrina Baroni flowering
by: Aihua Guo, et al.
Published: (2023-01-01)

Multi-omics data reveals the disturbance of glycerophospholipid metabolism caused by disordered gut microbiota in depressed mice
by: Tian Tian, et al.
Published: (2022-07-01)

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
by: Michael A. Nauck, et al.
Published: (2021-04-01)

Untargeted Plasma Lipidomics Reveal Perturbed Metabolites of Glycerophospholipids, and Sphingolipids in Moderate-to-Severe Acne
by: Zhang D, et al.
Published: (2023-08-01)

Verbascoside exerts an anti-atherosclerotic effect by regulating liver glycerophospholipid metabolism
by: Peng Lei, et al.
Published: (2023-11-01)

Dulaglutide treatment reverses depression‐like behavior and hippocampal metabolomic homeostasis in mice exposed to chronic mild stress
by: Man Jin, et al.
Published: (2024-03-01)

Effects of dulaglutide combined with insulin degludec on glucose fluctuations and appetite in type 2 diabetes
by: Jinxin Huang, et al.
Published: (2023-05-01)

Glycerophospholipid Supplementation as a Potential Intervention for Supporting Cerebral Structure in Older Adults
by: Jeffery M. Reddan, et al.
Published: (2018-03-01)

The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults [version 2; peer review: 2 approved]
by: Sharon Lechtig-Wassermann, et al.
Published: (2023-12-01)

An observational study evaluating effectiveness and therapeutic adherence in patients with Type 2 Diabetes initiating dulaglutide vs. subcutaneous semaglutide in Spain
by: Santiago Tofé, et al.
Published: (2021-03-01)

Liraglutide Drug Loading with Double Layered Hydroxide- Synthesis and Characterization
by: Sevan Adeeb Doshan, et al.
Published: (2020-06-01)